Trial Profile

The Efficacy and Safety of Winlevi in Skin of Color Patients With Acne

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 30 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Clascoterone (Primary)
Indications Acne vulgaris
Focus Therapeutic Use
Sponsors Sun Pharmaceutical Industries

Most Recent Events

25 Oct 2024 According to a Sun Pharma media release, company announced today , interim analysis 16-week data from this trial will be presented in a poster at the 44th Annual Fall Clinical Dermatology Conference, being held Oct 24-27, 2024, in Las Vegas, Nevada.
25 Oct 2024 Primary endpoint has been met (The primary endpoint of this study is the percent of patients who achieve clear or almost clear on IGA at week 16) , according to Interim results presented in a Sun Pharmaceutical Industries media release
25 Oct 2024 Interim results presented in a Sun Pharmaceutical Industries media release

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com